Proteomic Classification of Breast Cancer

Author(s): Dalia Kamel, Bernadette Brady, Adel Tabchy, Gordon B. Mills, Bryan Hennessy

Journal Name: Current Drug Targets

Volume 13 , Issue 12 , 2012

Become EABM
Become Reviewer


Being a significant health problem that affects patients in various age groups, breast cancer has been extensively studied to date. Recently, molecular breast cancer classification has advanced significantly with the availability of genomic profiling technologies. Proteomic technologies have also advanced from traditional protein assays including enzyme- linked immunosorbent assay, immunoblotting and immunohistochemistry to more comprehensive approaches including mass spectrometry and reverse phase protein lysate arrays (RPPA). The purpose of this manuscript is to review the current protein markers that influence breast cancer prediction and prognosis and to focus on novel advances in proteomic classification of breast cancer.

Keywords: Breast cancer, proteome, RPPA, molecular technology, genomic profiling, reverse phase protein lysate arrays(RPPA), mass spectrometry, human genome, Epidermal Growth Factor Receptor (EGFR), genomic technologies.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Page: [1495 - 1509]
Pages: 15
DOI: 10.2174/138945012803530080
Price: $65

Article Metrics

PDF: 26